Correction: Nanostructured lipid carrier (NLC)-based novel hydrogels as potential carriers for nepafenac applied after cataract surgery for the treatment of inflammation: design, characterization and in vitro cellular inhibition and uptake studies

Shihui Yu; Guoxin Tan; Dandan Liu; Xinggang Yang; Weisan Pan

doi:10.1039/C7RA90048A

You do not have JavaScript enabled. Please enable JavaScript to access the full features of the site or access our non-JavaScript page.

Correction: Nanostructured lipid carrier (NLC)-based novel hydrogels as potential carriers for nepafenac applied after cataract surgery for the treatment of inflammation: design, characterization and in vitro cellular inhibition and uptake studies

Shihui Yu,^a Guoxin Tan,^a Dandan Liu,^b Xinggang Yang*^a and Weisan Pan*^a

Author affiliations

* Corresponding authors

^a Department of Pharmaceutics, School of Pharmacy, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang 110016, China
E-mail: pppwwwsss@163.com, yangxg123@163.com

^b School of Biomedical & Chemical Engineering, Liaoning Institute of Science and Technology, Benxi 117004, PR China

Abstract

Correction for ‘Nanostructured lipid carrier (NLC)-based novel hydrogels as potential carriers for nepafenac applied after cataract surgery for the treatment of inflammation: design, characterization and in vitro cellular inhibition and uptake studies’ by Shihui Yu et al., RSC Adv., 2017, 7, 16668–16677.

Download options Please wait...

Associated articles

Nanostructured lipid carrier (NLC)-based novel hydrogels as potential carriers f…

Article information

DOI: https://doi.org/10.1039/C7RA90048A
Article type: Correction
Submitted: 22 Mar 2017
Accepted: 22 Mar 2017
First published: 18 Apr 2017
This article is Open Access

Download Citation

RSC Adv., 2017,7, 21475-21475

Permissions

Request permissions

Correction: Nanostructured lipid carrier (NLC)-based novel hydrogels as potential carriers for nepafenac applied after cataract surgery for the treatment of inflammation: design, characterization and in vitro cellular inhibition and uptake studies

S. Yu, G. Tan, D. Liu, X. Yang and W. Pan, RSC Adv., 2017, 7, 21475 DOI: 10.1039/C7RA90048A

This article is licensed under a Creative Commons Attribution 3.0 Unported Licence. You can use material from this article in other publications without requesting further permissions from the RSC, provided that the correct acknowledgement is given.

Social activity

Fetching data from CrossRef.
This may take some time to load.

RSC Advances

Correction: Nanostructured lipid carrier (NLC)-based novel hydrogels as potential carriers for nepafenac applied after cataract surgery for the treatment of inflammation: design, characterization and in vitro cellular inhibition and uptake studies

Abstract

Associated articles

Article information

Download Citation

Permissions

Correction: Nanostructured lipid carrier (NLC)-based novel hydrogels as potential carriers for nepafenac applied after cataract surgery for the treatment of inflammation: design, characterization and in vitro cellular inhibition and uptake studies

Social activity

Search articles by author

Spotlight

Advertisements